The American Medical Association is urging Optum, a unit of UnitedHealth Group, to ease up on recouping the loans it provided ...

After accumulating $86 billion in global sales, Amgen is still trying to keep Enbrel biosimilars off the market, Sandoz ...

In a development landscape as extensive as obesity, we think Pfizer could be better served by looking outside,' Stifel ...

The government is fighting in court for a plan to cut spending on overhead research costs for grantees. Primate centers fear ...

Commerce Secretary Howard Lutnick has indicated more specific timelines as to when pharma tariffs could surface, noting they ...

Pfizer discontinues obesity pill danuglipron after potential drug-induced liver injury in trial patient; company has GIP ...

Verve Therapeutics is trying to swerve the gene editing industry downturn with new results on a potential one-time treatment to lower cholesterol. The experimental gene editing therapy cut bad ...

Scientists develop STITCHR, a retrotransposon-based gene editing tool, by Omar Abudayyeh (Mass General Brigham) and Jonathan ...

After 17 years at Genentech, Ira Mellman is joining the Parker Institute for Cancer Immunotherapy as president of research.

Under the 11-page 'roadmap' outlined Thursday, the goal is for animal testing to become 'the exception rather than the norm' ...

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

It’s a biotech environment without many good choices. Even before President Donald Trump’s tariff announcement pushed stock ...